European Biotechs Fire up Deals to Develop Parkinson’s Treatments
Last month, European biotechs Ipsen and AC Immune announced multi-million euro deals to acquire or…
12/08/2021 - 4 minutes
Ipsen
Ipsen Resumes Phase III Testing for Rare Disease Drug and Abandons Pediatric Trial
The French pharmaceutical company Ipsen has restarted the dosing of its treatment for a rare…
31/03/2020 - 4 minutes
12 European Biotechs which ‘stole the show’ at World most Important Cancer Meeting
Pharma and Biotech from every corner flocked to Chicago for the beginning of June. Why?…
08/06/2016 - 7 minutes
French Ipsen closes €700M deal for Californian Cancer Drug
Ipsen is paying Exelixis $200M upfront, plus $545M in future milestones to acquire commercialization rights…
01/03/2016 - 2 minutes
After Failing Phase III, Active Biotech is back to square one
Unfortunately, the Biotech world is not only composed of success stories. Active Biotech, a Swedish company…
02/06/2015 - 2 minutes
Ipsen buys an option to Acquire Canbex
Canbex, a spin-off of University College London (UCL) that raised a Series A financing of…
25/02/2015 - 2 minutes
